Summit Wealth Group (Colorado)’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,545
Closed -$303K 346
2025
Q3
$303K Buy
+1,545
New +$245K 0.03% 354

Other funds holding CRL

Summit Wealth Group (Colorado)'s CRL Position: Q4 2025 in Review

Summit Wealth Group (Colorado) sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 1,545 shares — an estimated $303K sold.

Summit Wealth Group (Colorado) first reported a position in CRL in Q3 2025 and held it in 1 quarter. The position peaked at $303K in Q3 2025. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Summit Wealth Group (Colorado) reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Summit Wealth Group (Colorado) sold 1,545 Charles River Laboratories shares in Q4 2025, an estimated $303K.
  • Summit Wealth Group (Colorado) first reported a position in Charles River Laboratories in Q3 2025 and held it in 1 quarter.
  • Summit Wealth Group (Colorado)'s Charles River Laboratories position peaked at $303K in Q3 2025.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Summit Wealth Group (Colorado)'s 13F filing for Q4 2025, filed 4 Feb 2026.